|
gptkbp:instanceOf
|
benzodiazepine
sedative
|
|
gptkbp:ATCCode
|
N05CD02
|
|
gptkbp:brand
|
gptkb:Alodorm
gptkb:Mogadon
Pacisyn
|
|
gptkbp:CASNumber
|
146-22-5
|
|
gptkbp:color
|
white (as powder)
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
yes
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
16-38 hours
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:hasInChIKey
|
GOLXRNDWAUTYKT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C15H11N3O3
|
|
gptkbp:hasSMILES
|
O=C1CN=C(C2=CC=CC=C2)C2=CC([N+](=O)[O-])=CC=C2N1
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nitrazepam
|
|
gptkbp:introducedIn
|
1965
|
|
gptkbp:IUPACName
|
1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptor
|
|
gptkbp:meltingPoint
|
227–228 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
4494
4340
DB01595
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
dizziness
muscle relaxation
drowsiness
impaired coordination
|
|
gptkbp:synonym
|
gptkb:Nipam
gptkb:Nitrazadon
|
|
gptkbp:UNII
|
3Z8Z49P0F5
|
|
gptkbp:usedFor
|
treatment of epilepsy
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|